evixapodlin   Click here for help

GtoPdb Ligand ID: 11684

Synonyms: compound 139 [WO2019160882A1] | GS-4224 | GS4224 | PD-1/PD-L1-IN 7
Compound class: Synthetic organic
Comment: We obtained the chemical structure for evixapodlin from WHO Proposed list 125 of July 2021. The INN record describes it as a programmed cell death ligand 1 (PD-L1) inhibitor. Evixapodlin is one of the chemical structures that is claimed in Gilead Sciences' patent WO2019160882A1 (compound number 139) [1]. It was developed as an alternative to monocloncal antibody PD-L1/PD-1 interaction inhibitors, for potential anticancer and antiviral activities. First disclosures at the ACS meeting in Chicago in 2022 mapped evixapodlin to Gilead's clinical lead GS-4224. GS-4224 is orally bioavailable.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 152.28
Molecular weight 690.22
XLogP 3.77
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)c1cccc(c1Cl)c1cccc(c1Cl)c1cnc(c(n1)OC)CNC[C@@H]1CCC(=O)N1
Isomeric SMILES COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)c1cccc(c1Cl)c1c(c(ccc1)c1cnc(c(n1)OC)CNC[C@@H]1CCC(=O)N1)Cl
InChI InChI=1S/C34H36Cl2N8O4/c1-47-33-27(15-37-13-19-9-11-29(45)41-19)39-17-25(43-33)23-7-3-5-21(31(23)35)22-6-4-8-24(32(22)36)26-18-40-28(34(44-26)48-2)16-38-14-20-10-12-30(46)42-20/h3-8,17-20,37-38H,9-16H2,1-2H3,(H,41,45)(H,42,46)/t19-,20-/m0/s1
InChI Key OIIOPWHTJZYKIL-PMACEKPBSA-N
References
1. Aktoudianakis E, Cho A, Du Z, Graupe M, Lad LT, Machicao Tello PA, Medley JW, Metobo SE, Mukherjee PK, Naduthambi D et al.. (2019)
Pd-1/pd-l1 inhibitors.
Patent number: WO2019160882A1. Assignee: Gilead Sciences, Inc.. Priority date: 13/02/2018. Publication date: 22/08/2019.